Phase II Study of XKH001 Injection in Moderate to Severe COPD

Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing XKH001 injection with Placebo injection (2 arms). Primary endpoints: Change from baseline in post-bronchodilator FEV1 (mL) at Week 28 and Treatment-emergent adverse events (TEAEs): incidence, severity, and relationship to investigational product; changes in safety assessments. Planned start Apr 2026; status: not yet recruiting.